|
Apr 30
|
Is Roche Holding (RHHBY) Stock Outpacing Its Medical Peers This Year?
|
|
Apr 30
|
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
|
|
Apr 29
|
FDA grants breakthrough status to Roche’s VENTANA TROP2 device
|
|
Apr 29
|
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
|
|
Apr 25
|
Roche’s diagnostic sales hit by China pricing reforms
|
|
Apr 18
|
Stocks to watch next week: Tesla, Alphabet, Intel, Boeing and Unilever
|
|
Apr 17
|
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
|
|
Apr 14
|
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
|
|
Apr 14
|
Roche’s Columvi combo gains EC approval for DLBCL
|
|
Apr 14
|
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
|
|
Mar 14
|
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
|
|
Mar 14
|
Roche Diagnostics supports UK eye cancer AI initiative
|
|
Mar 14
|
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
|
|
Mar 13
|
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|
|
Mar 13
|
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
|
|
Mar 12
|
Roche, Zealand sign deal: What it means for weight loss drug space
|
|
Mar 12
|
Novo Nordisk Is Falling. Competition Is a Killer.
|
|
Mar 12
|
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
|
|
Mar 12
|
Novo Nordisk, Starbucks shares slumping: Trending Tickers
|